R
Raffaele Bruno
Researcher at University of Pavia
Publications - 322
Citations - 14690
Raffaele Bruno is an academic researcher from University of Pavia. The author has contributed to research in topics: Medicine & Hepatitis C. The author has an hindex of 52, co-authored 275 publications receiving 11262 citations. Previous affiliations of Raffaele Bruno include University of Modena and Reggio Emilia.
Papers
More filters
Journal ArticleDOI
Patients with chronic hepatitis C receiving treatment with direct acting antivirals: How is this population changing?
Andrea Lombardi,Marta Colaneri,Kesav Aditya Vijayagopal,Margherita Sambo,Patrizia Legnazzi,Paolo Sacchi,Valentina Zuccaro,Laura Maiocchi,Renato Maserati,Roberto Gulminetti,Layla Pagnucco,Stefano Novati,D. Zanaboni,G. Michelone,Serena Ludovisi,Mario U. Mondelli,Raffaele Bruno +16 more
TL;DR: The population of patients with CHC receiving DAAs is becoming older and with more comorbidities, Nevertheless, this did not impact SVR rates.
Journal ArticleDOI
Vaccination for seasonal influenza, pneumococcal infection and SARS-CoV-2 in patients with solid tumors: recommendations of the Associazione Italiana di Oncologia Medica (AIOM)
Paolo Pederzoli,Angioletta Lasagna,Irene Cassaniti,Antonio Piralla,A Squeri,Raffaele Bruno,Paolo Macchi,Fausto Baldanti,M. Di Maio,Giordano D. Beretta,Saverio Cinieri,Nicola Silvestris +11 more
TL;DR: In this article , the authors report the recommendations of the Italian Association of Medical Oncology about these vaccinations in adult patients with solid tumors, and they believe that a multidisciplinary care model may improve the vaccination coverage in immunocompromised patients.
Journal ArticleDOI
Analisi di cost-consequence della duplice e triplice terapia nel trattamento dell’epatite cronica di tipo C genotipo 1 in pazienti adulti naïve con fibrosi F0–F2
TL;DR: Regardless of the protease inhibitor administered, from the Italian NHS perspective, starting the treatment with pegylated interferon α-2a plus ribavirin is a cost-saving strategy compared with starting with peginterferonα-2b plus ribvirin.
Journal ArticleDOI
Will direct-acting antivirals make a difference in HIV-HCV coinfected patients?
TL;DR: Both telaprevir (TVR) and boceprevir (BOC) are potent inhibitors of the NS3/4A serine protease; both have been tested in combination with the standard-of-care (SOC; peginterferon plus ribavirin) in large Phase III trials as mentioned in this paper.
Journal ArticleDOI
Impact of rifaximin in the prevention of bacterial infections in cirrhosis
M. Mariani,Luigia Scudeller,S.F.A. Patruno,Valentina Zuccaro,P. Columpsi,S. Toppino,Antonello Malfitano,A. Parisi,Gaetano Filice,Raffaele Bruno +9 more
TL;DR: In this article, the authors retrospectively investigated the rate of infections in hospitalized cirrhotic patients under treatment with rifaximin, and they found that the risk of developing selected bacterial infections was significantly lower in patients treated with RXI (OR 0.29; 95% CI 0.20-0.40, p < 0.001).